Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Theravance Biopharma Inc (TBPH) USD0.00001

Sell:$16.57 Buy:$18.65 Change: $0.18 (1.06%)
NASDAQ:0.40%
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$16.57
Buy:$18.65
Change: $0.18 (1.06%)
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$16.57
Buy:$18.65
Change: $0.18 (1.06%)
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company's pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Its Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.

Contact details

Address:
UGLAND HOUSE, SOUTH CHURCH STREET
GEORGE TOWN
KY1-1104
Cayman Islands
Telephone:
+1 (345) 6508086000
Website:
www.theravance.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
TBPH
ISIN:
KYG8807B1068
Market cap:
$955.75 million
Shares in issue:
56.64 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
Cayman Islands
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Rick Winningham
    Chairman of the Board, Chief Executive Officer
  • Andrew Hindman
    Chief Financial Officer, Senior Vice President
  • Ann Brady
    President - Theravance Biopharma Ireland Limited
  • Bradford Shafer
    Executive Vice President, General Counsel, Secretary
  • .. ..
    Senior Vice President - Technical Operations
  • Brett Haumann
    Senior Vice President, Clinical Development and Chief Medical Officer
  • Sharathchandra Hegde
    Senior Vice President - Research
  • Frank Pasqualone
    Senior Vice President and Chief Commercial Operations Officer
  • Kenneth Pitzer
    Senior Vice President - Product Strategy and Commercial Planning
  • Shehnaaz Suliman
    Senior Vice President - Corporate Development and Strategy

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.